Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib-Reference-Cited by-同舟云学术

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Published:2015-03-26 Issue:13 Volume:125 Page:2062-2067
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Jain Preetesh¹²,Keating Michael¹,Wierda William¹,Estrov Zeev¹,Ferrajoli Alessandra¹,Jain Nitin¹,George Binsah¹,James Danelle³,Kantarjian Hagop¹,Burger Jan¹,O’Brien Susan¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Internal Medicine, University of Texas Medical School at Houston, Houston, TX; and

3. Pharmacyclics, Inc, Sunnyvale, CA

Abstract

Key Points Clinical characteristics, causes of discontinuation, and outcome of patients who progress or fail ibrutinib are described. Patients with CLL who progress early on ibrutinib therapy have poor outcomes.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/13/2062/1383568/2062.pdf

Reference10 articles.

1. B-cell receptor signaling as a driver of lymphoma development and evolution.;Niemann;Semin Cancer Biol,2013

2. Targeting Bruton’s tyrosine kinase in B cell malignancies.;Hendriks;Nat Rev Cancer,2014

3. The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study.;O'Brien;Blood,2013

4. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

5. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.;Burger;Lancet Oncol,2014

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia;Leukemia;2024-06-24

2. Impaired Cardiac AMPK (5′‐Adenosine Monophosphate‐Activated Protein Kinase) and Ca ²⁺ ‐Handling, and Action Potential Duration Heterogeneity in Ibrutinib‐Induced Ventricular Arrhythmia Vulnerability;Journal of the American Heart Association;2024-06-18

3. PET/CT in leukemia: utility and future directions;Nuclear Medicine Communications;2024-04-22

4. Prognostication in chronic lymphocytic leukemia;Seminars in Hematology;2024-04

5. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia;Seminars in Hematology;2024-04